Sarah A. O'Dowd - 02 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Reporting relationship: Director
Issuer ticker: PTGX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 19:39:35 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Gosling, Attorney-in-Fact for Sarah A. O'Dowd

Key filing fact

Sarah A. O'Dowd filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 06 Jan 2026.

Key facts

This page summarizes Sarah A. O'Dowd's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 19:39.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001447149 Primary reporting owner

O'Dowd Sarah A

Relationship: Director
Address: C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Sarah A. O'Dowd
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTGX transaction

Common Stock

Award

Transaction value: $0
Shares: +2,695
Change %: +53%
Price: $0.000000
Shares after: 7,825
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTGX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +3,762
Change %
Price: $0.000000
Shares after: 3,762
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,762
Exercise price: $87.18
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Footnote F2

The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.